Citius Pharmaceuticals (CTXR) Short Interest Ratio & Short Volume → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free CTXR Stock Alerts $0.70 +0.04 (+6.08%) (As of 05/31/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Citius Pharmaceuticals Short Interest DataCurrent Short Interest14,480,000 sharesPrevious Short Interest14,430,000 sharesChange Vs. Previous Month+0.35%Dollar Volume Sold Short$9.05 millionShort Interest Ratio10.5 Days to CoverLast Record DateMay 15, 2024Outstanding Shares180,670,000 sharesPercentage of Shares Shorted8.01%Today's Trading Volume1,969,316 sharesAverage Trading Volume2,398,558 sharesToday's Volume Vs. Average82% Short Selling Citius Pharmaceuticals ? Sign up to receive the latest short interest report for Citius Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCTXR Short Interest Over TimeCTXR Days to Cover Over TimeCTXR Percentage of Float Shorted Over Time Ad Behind the MarketsDon’t buy a single NVIDIA share before you see this...If you feel like NVIDIA is still a good buy - be careful. Billionaires like Steve Cohen, Stanley Druckenmiller and George Soros are ALL dumping NVIDIA... And piling into an overlooked sector...I've prepared a short briefing with all the proof Citius Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202414,480,000 shares $9.05 million +0.4%N/A10.5 $0.62 4/30/202414,430,000 shares $10.77 million +9.4%N/A15.6 $0.75 4/15/202413,190,000 shares $10.09 million +6.1%N/A15.5 $0.77 3/31/202412,430,000 shares $11.15 million +2.1%N/A16.9 $0.90 3/15/202412,180,000 shares $8.97 million +2.7%N/A18.6 $0.74 2/29/202411,860,000 shares $9.11 million +2.4%N/A18.9 $0.77 Get the Latest News and Ratings for CTXR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/15/202411,580,000 shares $9.75 million -0.3%N/A18.5 $0.84 1/31/202411,610,000 shares $7.21 million -16.7%N/A20.2 $0.62 1/15/202413,940,000 shares $10.46 million -4.7%N/A23.6 $0.75 12/31/202314,620,000 shares $11.06 million +8.6%N/A26.2 $0.76 12/15/202313,460,000 shares $10.73 million -15.0%N/A25.1 $0.80 11/30/202315,830,000 shares $12.20 million -1.3%N/A25.1 $0.77 11/15/202316,030,000 shares $12.31 million -5.1%N/A25.1 $0.77 10/31/202316,890,000 shares $12.71 million -1.9%N/A23.3 $0.75 10/15/202317,210,000 shares $12.00 million -7.2%N/A17.3 $0.70 9/30/202318,540,000 shares $12.69 million -4.5%N/A18 $0.68 9/15/202319,420,000 shares $14.74 million -1.1%N/A15.9 $0.76 8/31/202319,640,000 shares $17.92 million -1.1%N/A13.3 $0.91 8/15/202319,850,000 shares $17.10 million -4.6%N/A12.7 $0.86 7/31/202320,800,000 shares $20.59 million +2.0%N/A10.8 $0.99 7/15/202320,390,000 shares $24.26 million +8.7%N/A11 $1.19 6/30/202318,760,000 shares $22.51 million +27.9%N/A9.9 $1.20 6/15/202314,670,000 shares $18.48 million +6.6%N/A8.2 $1.26 5/31/202313,760,000 shares $15.96 million +13.4%N/A9.5 $1.16 5/15/202312,130,000 shares $15.53 million -10.8%N/A8.9 $1.28 4/30/202313,600,000 shares $19.72 million +6.7%N/A14.3 $1.45 4/15/202312,750,000 shares $20.91 million +6.5%9.5%14 $1.64 3/31/202311,970,000 shares $14.00 million +4.5%8.9%13.5 $1.17 3/15/202311,450,000 shares $11.79 million +1.5%8.6%13.1 $1.03 2/28/202311,280,000 shares $12.97 million +2.8%8.4%13.6 $1.15 2/15/202310,970,000 shares $13.49 million -5.4%8.2%13.5 $1.23 1/31/202311,600,000 shares $16.12 million +6.6%8.7%14.9 $1.39 1/15/202310,880,000 shares $12.19 million -0.7%8.1%15.3 $1.12 12/30/202210,960,000 shares $8.66 million -3.4%8.2%22 $0.79 12/15/202211,340,000 shares $12.81 million -0.4%N/A23.1 $1.13 11/30/202211,390,000 shares $13.33 million +4.5%N/A23.2 $1.17 11/15/202210,900,000 shares $11.66 million +1.3%N/A22.2 $1.07 10/31/202210,760,000 shares $11.62 million -3.0%N/A19.2 $1.08 10/15/202211,090,000 shares $11.98 million -0.1%N/A19.5 $1.08 9/30/202211,100,000 shares $13.43 million +6.3%N/A17.8 $1.21SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. 9/15/202210,440,000 shares $12.84 million +3.6%N/A12.7 $1.23 8/31/202210,080,000 shares $12.40 million +2.0%N/A11.1 $1.23 8/15/20229,880,000 shares $12.55 million -0.7%N/A9.1 $1.27 7/31/20229,950,000 shares $8.89 million -4.8%N/A7.8 $0.89 7/15/202210,450,000 shares $9.54 million +1.1%N/A6.6 $0.91 6/30/202210,340,000 shares $9.51 million -29.1%N/A5.2 $0.92 6/15/202214,590,000 shares $13.92 million -2.7%N/A7.1 $0.95 5/31/202214,990,000 shares $14.09 million +7.2%11.2%7.9 $0.94 5/15/202213,990,000 shares $12.52 million +5.7%10.5%7.6 $0.90 4/30/202213,230,000 shares $13.36 million +25.1%9.9%7.1 $1.01 4/15/202210,580,000 shares $16.40 million +13.6%7.9%6.3 $1.55 3/31/20229,310,000 shares $16.66 million +2.4%7.0%6.2 $1.79 3/15/20229,090,000 shares $14.36 million +1.8%6.8%6.9 $1.58 2/28/20228,930,000 shares $13.75 million -11.2%6.7%6.2 $1.54 2/15/202210,060,000 shares $16.40 million -6.1%7.5%6.5 $1.63 1/31/202210,710,000 shares $16.17 million -5.3%8.0%6.7 $1.51 1/15/202211,310,000 shares $17.30 million -7.0%8.5%6.7 $1.53 12/31/202112,160,000 shares $18.73 million -7.3%9.1%6.6 $1.54 12/15/202113,110,000 shares $22.29 million +2.5%9.8%6.7 $1.70 11/30/202112,790,000 shares $21.62 million -5.0%9.6%6.2 $1.69 11/15/202113,460,000 shares $24.36 million -7.0%10.1%5.6 $1.81 10/29/202114,470,000 shares $27.06 million +2.1%10.8%5.9 $1.87 10/15/202114,170,000 shares $29.62 million -2.0%10.6%5.3 $2.09 9/30/202114,460,000 shares $29.35 million +0.4%10.8%4.9 $2.03 9/15/202114,410,000 shares $29.25 million +11.2%10.8%2.6 $2.03 8/31/202112,960,000 shares $29.16 million -5.4%9.8%1.6 $2.25 8/13/202113,700,000 shares $24.80 million -6.0%10.3%1.6 $1.81 7/30/202114,570,000 shares $27.54 million -13.9%11.8%1.7 $1.89 7/15/202116,920,000 shares $32.49 million -20.9%13.7%1.7 $1.92 6/30/202121,400,000 shares $74.47 million +40.4%17.4%2.1 $3.48 6/15/202115,240,000 shares $49.23 million -3.7%12.4%2 $3.23 5/28/202115,820,000 shares $36.07 million +8.6%12.9%2.5 $2.28 5/14/202114,570,000 shares $27.54 million +24.3%N/A1.7 $1.89 4/30/202111,720,000 shares $24.73 million -10.4%N/A0.8 $2.11 4/15/202113,080,000 shares $23.54 million +18.6%N/A0.9 $1.80 3/31/202111,030,000 shares $20.41 million +51.3%N/A0.8 $1.85 3/15/20217,290,000 shares $13.92 million -27.9%N/A0.6 $1.91 2/26/202110,110,000 shares $20.83 million +261.1%N/A0.9 $2.06 2/12/20212,800,000 shares $3.81 million +15.7%N/A0.3 $1.36 1/29/20212,420,000 shares $2.90 million +112.3%N/A1.6 $1.20 1/15/20211,140,000 shares $1.30 million -9.5%N/A1.4 $1.14 12/31/20201,260,000 shares $1.31 million -23.6%N/A1.8 $1.04 12/15/20201,650,000 shares $1.77 million +71.8%N/A2.2 $1.07 11/30/2020960,600 shares $947,824.02 -20.0%N/A1.2 $0.99 11/15/20201,200,000 shares $1.15 million -9.1%N/A1.6 $0.95 10/30/20201,320,000 shares $1.33 million +6.5%N/A1.6 $1.01 10/15/20201,240,000 shares $1.33 million +53.3%N/A1.1 $1.07 9/30/2020809,100 shares $841,464.00 +15.4%N/A0.6 $1.04 9/15/2020701,200 shares $743,272.00 -8.9%N/A0.2 $1.06 8/31/2020769,400 shares $715,542.00 +4.6%N/A0.3 $0.93SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. 8/14/2020735,600 shares $787,092.00 -59.8%N/A0.2 $1.07 7/31/20201,830,000 shares $2.36 million +28.0%N/A0.5 $1.29 7/15/20201,430,000 shares $1.70 million -56.1%N/A0.4 $1.19 6/30/20203,260,000 shares $3.68 million +242.3%N/A1.1 $1.13 6/15/2020952,300 shares $842,595.04 +10.0%N/A0.6 $0.88 5/29/2020865,500 shares $751,254.00 -33.4%N/A0.6 $0.87 5/15/20201,300,000 shares $1.05 million +9.2%N/A1.1 $0.81 4/30/20201,190,000 shares $1.09 million +92.7%N/A1.4 $0.92 4/15/2020617,500 shares $432,188.25 +13.8%N/A0.9 $0.70 3/31/2020542,800 shares $439,668.00 +31.1%2.5%0.7 $0.81 3/13/2020414,200 shares $281,656.00 -5.2%1.9%0.8 $0.68 2/28/2020436,900 shares $200,974.00 -64.8%2.0%0.7 $0.46 2/14/20201,240,000 shares $731,600.00 +10.7%6.6%2 $0.59 1/31/20201,120,000 shares $896,000.00 +13.4%7.4%2 $0.80 1/15/2020988,000 shares $1.02 million -21.0%6.6%2 $1.03 12/31/20191,250,000 shares $1.56 million +303.5%8.3%3.5 $1.25 CTXR Short Interest - Frequently Asked Questions What is Citius Pharmaceuticals' current short interest? Short interest is the volume of Citius Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 14,480,000 shares of CTXR short. Learn More on Citius Pharmaceuticals' current short interest. What is a good short interest ratio for Citius Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CTXR shares currently have a short interest ratio of 10.0. Learn More on Citius Pharmaceuticals's short interest ratio. Which institutional investors are shorting Citius Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Citius Pharmaceuticals: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Citius Pharmaceuticals' short interest increasing or decreasing? Citius Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 14,480,000 shares, an increase of 0.3% from the previous total of 14,430,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Citius Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Citius Pharmaceuticals: Vistagen Therapeutics, Inc. (4.36%), Daré Bioscience, Inc. (0.53%), Merrimack Pharmaceuticals, Inc. (5.70%), KalVista Pharmaceuticals, Inc. (13.65%), PepGen Inc. (1.61%), Travere Therapeutics, Inc. (17.65%), Applied Therapeutics, Inc. (4.00%), Annexon, Inc. (8.19%), Erasca, Inc. (6.60%), Korro Bio, Inc. (2.81%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Citius Pharmaceuticals stock? Short selling CTXR is an investing strategy that aims to generate trading profit from Citius Pharmaceuticals as its price is falling. CTXR shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Citius Pharmaceuticals? A short squeeze for Citius Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CTXR, which in turn drives the price of the stock up even further. How often is Citius Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CTXR, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Vistagen Therapeutics Short Interest Data Daré Bioscience Short Interest Data Merrimack Pharmaceuticals Short Interest Data KalVista Pharmaceuticals Short Interest Data PepGen Short Interest Data Travere Therapeutics Short Interest Data Applied Therapeutics Short Interest Data Annexon Short Interest Data Erasca Short Interest Data Korro Bio Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CTXR) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.